MIM
XENE icon

MetLife Investment Management’s Xenon Pharmaceuticals XENE Stock Holding History

MetLife Investment Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.75M Buy
47,343
+5,318
+13% +$245K 0.01% 894
2025
Q4 		$1.88M Sell
42,025
-2,196
-5% -$92.2K 0.01% 1101
2025
Q3 		$1.78M Sell
44,221
-1,326
-3% -$46.7K 0.01% 1145
2025
Q2 		$1.43M Buy
+45,547
New +$1.49M 0.01% 1148

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MetLife Investment Management's XENE Position: Q1 2026 in Review

MetLife Investment Management increased its Xenon Pharmaceuticals (XENE) stake by 13% in Q1 2026, buying an estimated $245K and bringing the position to 47,343 shares worth $2.75M. The position accounts for 0.01% of the portfolio, ranked #894.

MetLife Investment Management first reported a position in XENE in Q2 2025 and has held it in 4 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • MetLife Investment Management held 47,343 shares of Xenon Pharmaceuticals worth $2.75M as of Q1 2026.
  • MetLife Investment Management bought 5,318 Xenon Pharmaceuticals shares in Q1 2026, an estimated $245K.
  • Xenon Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #894 holding.
  • MetLife Investment Management first reported a position in Xenon Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.